These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16015525)

  • 1. Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
    Hassaballa HA; Lateef OB; Silver MR; Balk RA
    J Crit Care; 2005 Mar; 20(1):111-3. PubMed ID: 16015525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
    Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
    Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic trioxide for the treatment of myelodysplastic syndromes.
    Vey N
    Expert Opin Pharmacother; 2004 Mar; 5(3):613-21. PubMed ID: 15013929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
    Au WY; Lang BH; Fong BM; Mao KJ; Tam S
    Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
    [No Abstract]   [Full Text] [Related]  

  • 10. New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
    Sekeres MA
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
    Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
    Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk/benefit profile of arsenic trioxide.
    Rust DM; Soignet SL
    Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Camacho LH; Soignet SL; Chanel S; Ho R; Heller G; Scheinberg DA; Ellison R; Warrell RP
    J Clin Oncol; 2000 Jul; 18(13):2620-5. PubMed ID: 10893295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.